Methylation of the genes for the microRNAs miR-129-2 and miR-9-1, changes in their expression, and activation of their potential target genes in clear cell renal cell carcinoma


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Methylation of promoter CpG islands and microRNA (miRNA) interactions with mRNAs of target genes are epigenetic mechanisms that play a crucial role in deregulation of gene expression and signaling pathways in tumors. Altered expression of six chromosome 3p genes (RARB(2), SEMA3B, RHOA, GPX1, NKIRAS1, and CHL1) and two miRNA genes (MIR-129-2 and MIR-9-1) was observed in primary clear cell renal cell carcinomas (ccRCCs, 31–48 samples) by RT-PCR and qPCR. Significant downregulation (p < 0.05, Fisher’s exact test) was observed for SEMA3B, NKIRAS1, and CHL1; and differential expression, for the other chromosome 3p and miRNA genes. Methylation-specific PCR with primers to RARB(2), SEMA3B, MIR-129-2, and MIR-9-1 showed that their methylation frequency was significantly (p < 0.05, Fisher’s exact test) elevated in the ccRCC samples. Significant correlations between promoter methylation and expression were confirmed for SEMA3B and observed for the first time for RARB(2), GPX1, and MIR-129-2 in ccRCC (Spearman’s correlation coefficient rs ranging 0.31–0.60, p < 0.05). The MIR-129-2 and RARB(2) methylation frequencies significantly correlated with ccRCC progression. MIR-129-2 methylation correlated with upregulation of RARB(2), RHOA, NKIRAS1, and CHL1 (rs ranging 0.35–0.53, p < 0.05). The findings implicate methylation in regulating RARB(2), SEMA3B, GPX1, and MIR-129-2 and indicate that miR-129-2 and methylation of its gene affect RARB(2), RHOA, NKIRAS1, and CHL1 expression.

Sobre autores

I. Pronina

Research Centre of Medical Genetics; Institute of General Pathology and Pathophysiology

Autor responsável pela correspondência
Email: zolly_sten@mail.ru
Rússia, Moscow, 115478; Moscow, 125315

E. Klimov

Biological Faculty, Moscow State University

Email: zolly_sten@mail.ru
Rússia, Moscow, 119234

A. Burdennyy

Institute of General Pathology and Pathophysiology; Emanuel Institute of Biochemical Physics

Email: zolly_sten@mail.ru
Rússia, Moscow, 125315; Moscow, 119334

E. Beresneva

State Research Institute of Genetics and Selection of Industrial Microorganisms

Email: zolly_sten@mail.ru
Rússia, Moscow, 117545

M. Fridman

Vavilov Institute of General Genetics

Email: zolly_sten@mail.ru
Rússia, Moscow, 117971

V. Ermilova

Cancer Research Center

Email: zolly_sten@mail.ru
Rússia, Moscow, 115478

T. Kazubskaya

Cancer Research Center

Email: zolly_sten@mail.ru
Rússia, Moscow, 115478

A. Karpukhin

Research Centre of Medical Genetics

Email: zolly_sten@mail.ru
Rússia, Moscow, 115478

E. Braga

Research Centre of Medical Genetics; Institute of General Pathology and Pathophysiology

Email: zolly_sten@mail.ru
Rússia, Moscow, 115478; Moscow, 125315

V. Loginov

Research Centre of Medical Genetics; Institute of General Pathology and Pathophysiology

Email: zolly_sten@mail.ru
Rússia, Moscow, 115478; Moscow, 125315

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Pleiades Publishing, Inc., 2017